Literature DB >> 8113384

Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype.

H J Veeze1, D J Halley, J Bijman, J C de Jongste, H R de Jonge, M Sinaasappel.   

Abstract

Previous Ussing chamber measurements of secretagogue-provoked changes in short circuit current in rectal suction biopsies of cystic fibrosis (CF) patients showed that in a minority of patients chloride secretion in response to cholinergic agonists is reduced but not completely absent. To assess a possible relationship between this phenomenon and both the genotype and the phenotype, we performed Ussing chamber experiments on rectal suction biopsies of 51 CF patients. The CF mutation was identified in 89 out of 102 CF alleles. No apparent chloride secretion was found in 30 CF patients (group I). Low residual chloride secretion was found in 11 CF patients (group II), while a relatively high residual secretion appeared in 10 CF patients (group III). Pancreatic function was preserved more frequently in CF patients displaying residual secretion: 0% in group I, 27% in group II, and 60% in group III (P < 0.001). The age at diagnosis (mean +/- SEM) in group III (18.4 +/- 6.6) was significantly different from group I (1.2 +/- 0.4, P < 0.01) and group II (3.5 +/- 1.4, P = 0.05). Residual chloride secretion was found in some of the 28 dF508 homozygous patients (three in group II, and one in group III), disclosing that other factors than the CF gene defect itself affect the transepithelial chloride transport. The age at diagnosis correlates significantly with the magnitude of the secretory response, even within the dF508 homozygous patients (r = 0.4, P < 0.05). We conclude that residual chloride secretion in CF is the pathophysiological basis of preserved pancreatic function and delayed presentation of the disease, which is not exclusively determined by the CF genotype.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113384      PMCID: PMC293855          DOI: 10.1172/JCI116993

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  The mutation delta F508 on Dutch cystic fibrosis chromosomes: frequency and relation to patients age at diagnosis.

Authors:  D J Halley; H J Veeze; L A Sandkuyl; E Wesby-van Swaay; N H van Damme; W H Deelen; J E Witte; M F Niermeijer
Journal:  Hum Genet       Date:  1990-09       Impact factor: 4.132

2.  The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508).

Authors:  E Kerem; M Corey; B S Kerem; J Rommens; D Markiewicz; H Levison; L C Tsui; P Durie
Journal:  N Engl J Med       Date:  1990-11-29       Impact factor: 91.245

3.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

4.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis.

Authors:  S H Cheng; R J Gregory; J Marshall; S Paul; D W Souza; G A White; C R O'Riordan; A E Smith
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

5.  Prenatal detection of major cystic fibrosis mutation.

Authors:  D J Halley; N H van Damme; W H Deelen; B A Oostra; M G Jahoda; E S Sachs; F J Los; M F Niermeijer
Journal:  Lancet       Date:  1989-10-21       Impact factor: 79.321

6.  Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation.

Authors:  H K Johansen; M Nir; N Høiby; C Koch; M Schwartz
Journal:  Lancet       Date:  1991-03-16       Impact factor: 79.321

7.  Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis.

Authors:  H J Veeze; M Sinaasappel; J Bijman; J Bouquet; H R de Jonge
Journal:  Gastroenterology       Date:  1991-08       Impact factor: 22.682

8.  Demonstration that CFTR is a chloride channel by alteration of its anion selectivity.

Authors:  M P Anderson; R J Gregory; S Thompson; D W Souza; S Paul; R C Mulligan; A E Smith; M J Welsh
Journal:  Science       Date:  1991-07-12       Impact factor: 47.728

9.  Calcium and cAMP activate different chloride channels in the apical membrane of normal and cystic fibrosis epithelia.

Authors:  M P Anderson; M J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

10.  Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosis.

Authors:  G Santis; L Osborne; R A Knight; M E Hodson
Journal:  Lancet       Date:  1990-11-03       Impact factor: 79.321

View more
  26 in total

Review 1.  A mild variant of cystic fibrosis.

Authors:  E W Alton
Journal:  Thorax       Date:  1996-08       Impact factor: 9.139

2.  Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.

Authors:  Patrick A Flume; Theodore G Liou; Drucy S Borowitz; Haihong Li; Karl Yen; Claudia L Ordoñez; David E Geller
Journal:  Chest       Date:  2012-09       Impact factor: 9.410

3.  In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.

Authors:  Meghan E McGarry; Beate Illek; Ngoc P Ly; Lorna Zlock; Sabrina Olshansky; Courtney Moreno; Walter E Finkbeiner; Dennis W Nielson
Journal:  Pediatr Pulmonol       Date:  2017-01-09

4.  Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings.

Authors:  I Bronsveld; F Mekus; J Bijman; M Ballmann; H R de Jonge; U Laabs; D J Halley; H Ellemunter; G Mastella; S Thomas; H J Veeze; B Tümmler
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

5.  DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis.

Authors:  N Kälin; A Claass; M Sommer; E Puchelle; B Tümmler
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

6.  CFTR and differentiation markers expression in non-CF and delta F 508 homozygous CF nasal epithelium.

Authors:  F Dupuit; N Kälin; S Brézillon; J Hinnrasky; B Tümmler; E Puchelle
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

7.  A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo.

Authors:  P J French; J H van Doorninck; R H Peters; E Verbeek; N A Ameen; C R Marino; H R de Jonge; J Bijman; B J Scholte
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

8.  Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.

Authors:  Guido Veit; Radu G Avramescu; Doranda Perdomo; Puay-Wah Phuan; Miklos Bagdany; Pirjo M Apaja; Florence Borot; Daniel Szollosi; Yu-Sheng Wu; Walter E Finkbeiner; Tamas Hegedus; Alan S Verkman; Gergely L Lukacs
Journal:  Sci Transl Med       Date:  2014-07-23       Impact factor: 17.956

Review 9.  CFTR and defective endocytosis: new insights in the renal phenotype of cystic fibrosis.

Authors:  François Jouret; Olivier Devuyst
Journal:  Pflugers Arch       Date:  2008-10-07       Impact factor: 3.657

10.  GFP-tagged CFTR transgene is functional in the G551D cystic fibrosis mouse colon.

Authors:  D Oceandy; B McMorran; R Schreiber; B J Wainwright; K Kunzelmann
Journal:  J Membr Biol       Date:  2003-04-01       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.